The researchers, Dr. Atheer Majid Rashid and Dr. Janan Muhammad Mohsen from the College of Pharmacy at the University of Karbala and Dr. Adeeb Ahmed Al-Zubaidi from Al-Nahrain University, obtained a patent from the Central Agency for Standardization and Quality Control in the Iraqi Ministry of Planning to enable them to prove (the effectiveness of montelukast as a topical gel on emerging cutaneous psoriasis in mice).
The patent included preparation of montelukast gel, its topical application, and evaluation of its potential activity against psoriatic dermatitis.
The patent aims to prove the effectiveness of montelukast at concentrations of 0.05% and 0.1%, and that it significantly reduces the severity of psoriasis symptoms (severity of redness, scaling, and keratinization of the skin) and reduces inflammatory cytokines that provoke and stimulate the occurrence of psoriasis.
